financetom
Business
financetom
/
Business
/
Jubilant Foodworks set to secure 51.16% stake in DP Eurasia
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Jubilant Foodworks set to secure 51.16% stake in DP Eurasia
Nov 28, 2023 11:43 AM

Jubilant Foodworks is poised to secure an additional 51% stake in DP Eurasia for approximately ₹700 crore, equivalent to about 73 billion euros. DP Eurasia acts as the franchisor for Domino's Pizza in Turkey, Georgia, and Azerbaijan, with Russia no longer part of the equation.

Share Market Live

NSE

The acquisition, coupled with the existing 48.8% stake, will transform DP Eurasia into a wholly-owned subsidiary of Jubilant Foodworks. Consequently, the financial performance of DP Eurasia will be incorporated into Jubilant Foodworks' consolidated figures.

In 2021, Jubilant FoodWorks initially acquired a 33% stake for ₹251 crore. The subsequent growth in business has seen the valuations double. This move is expected to boost Jubilant FoodWorks' consolidated top-line and EBITDA by approximately 13 to 15%.

Read Here | Renaissance Investment prefers consumer discretionary, wary of 'crowded' QSR space

To finance this acquisition, Jubilant FoodWorks in India, while having some cash reserves, plans to establish a subsidiary in the Netherlands. This subsidiary will secure a loan, guaranteed by Jubilant FoodWorks in India, resulting in consolidated debt on the company's books.

DP Eurasia currently operates nearly 678 stores in Turkey, 10 in Azerbaijan, and 6 in Georgia. In the first half of the year, they generated revenues close to ₹456 crore, boasting margins of around 17% and a net profit of ₹66 crore.

Shares of Jubilant FoodWorks have settled at ₹544.80 in today’s trade. The stock is up more than 10% in the past month.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sector Update: Consumer Stocks Mixed Pre-Bell Tuesday
Sector Update: Consumer Stocks Mixed Pre-Bell Tuesday
Aug 20, 2024
09:15 AM EDT, 08/20/2024 (MT Newswires) -- Consumer stocks were mixed pre-bell Tuesday as the Consumer Staples Select Sector SPDR Fund ( XLP ) was advancing 0.02% and the Consumer Discretionary Select Sector SPDR Fund ( XLY ) was recently down 0.01%. Vipshop Holdings ( VIPS ) shares fell by nearly 7% after it reported lower Q2 non-GAAP earnings and...
Meta Platforms' Revised Rules on Advertising Data Use Accepted by UK Competition Regulator
Meta Platforms' Revised Rules on Advertising Data Use Accepted by UK Competition Regulator
Aug 20, 2024
09:17 AM EDT, 08/20/2024 (MT Newswires) -- Meta Platforms' ( META ) changes to rules on the way it uses data of advertising customers have been accepted by the UK's Competition and Markets Authority, the regulator said Tuesday. The CMA said that under the new approach that Meta plans to adopt, all advertisers can keep the ability to place advertisements...
Stellantis to Delay Reopening of Belvidere Assembly Plant
Stellantis to Delay Reopening of Belvidere Assembly Plant
Aug 20, 2024
08:40 AM EDT, 08/20/2024 (MT Newswires) -- Stellantis NV ( STLA ) has notified the United Auto Workers union that plans to reopen the Belvidere assembly plant in Illinois will be delayed, but it remains committed to the project, the company said Tuesday. To ensure the Company's future competitiveness and sustainability, which are necessary to preserve U.S. manufacturing jobs, it...
IGC Pharma Says Molecule IGC-1A Identified as Potential GLP-1 Agonist
IGC Pharma Says Molecule IGC-1A Identified as Potential GLP-1 Agonist
Aug 20, 2024
09:16 AM EDT, 08/20/2024 (MT Newswires) -- IGC Pharma ( IGC ) said Tuesday that its artificial intelligence modeling found molecule IGC-1A to be a potential glucagon-like peptide-1, or GLP-1, agonist. With this discovery, IGC Pharma ( IGC ) said it is positioned to potentially expand its drug portfolio to metabolic disorders and weight loss. GLP-1 agonists are known to...
Copyright 2023-2025 - www.financetom.com All Rights Reserved